Sqz Biotechnologies Co
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0508
- Today's High:
- $0.0567
- Open Price:
- $0.051
- 52W Low:
- $0.046
- 52W High:
- $3.388
- Prev. Close:
- $0.047
- Volume:
- 20966
Company Statistics
- Market Cap.:
- $12.83 million
- Book Value:
- 1.362
- Revenue TTM:
- $18.61 million
- Operating Margin TTM:
- -392.43%
- Gross Profit TTM:
- $-43050000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -33.32%
- Return on Equity TTM:
- -104.93%
Company Profile
Sqz Biotechnologies Co had its IPO on 2020-10-30 under the ticker symbol SQZ.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Sqz Biotechnologies Co has a staff strength of 53 employees.
Stock update
Shares of Sqz Biotechnologies Co opened at $0.05 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.05 - $0.06, and closed at $0.05.
This is a +8.09% increase from the previous day's closing price.
A total volume of 20,966 shares were traded at the close of the day’s session.
In the last one week, shares of Sqz Biotechnologies Co have slipped by -36.5%.
Sqz Biotechnologies Co's Key Ratios
Sqz Biotechnologies Co has a market cap of $12.83 million, indicating a price to book ratio of 0.4982 and a price to sales ratio of 1.2437.
In the last 12-months Sqz Biotechnologies Co’s revenue was $18.61 million with a gross profit of $-43050000 and an EBITDA of $-71585000. The EBITDA ratio measures Sqz Biotechnologies Co's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sqz Biotechnologies Co’s operating margin was -392.43% while its return on assets stood at -33.32% with a return of equity of -104.93%.
In Q2, Sqz Biotechnologies Co’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.3%.
Sqz Biotechnologies Co’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sqz Biotechnologies Co’s profitability.
Sqz Biotechnologies Co stock is trading at a EV to sales ratio of 0.5793 and a EV to EBITDA ratio of -0.1834. Its price to sales ratio in the trailing 12-months stood at 1.2437.
Sqz Biotechnologies Co stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $54.15 million
- Total Liabilities
- $9.91 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $47000
- Dividend Payout Ratio
- 0%
Sqz Biotechnologies Co ended 2024 with $54.15 million in total assets and $0 in total liabilities. Its intangible assets were valued at $54.15 million while shareholder equity stood at $24.54 million.
Sqz Biotechnologies Co ended 2024 with $0 in deferred long-term liabilities, $9.91 million in other current liabilities, 29000.00 in common stock, $-309431000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.71 million and cash and short-term investments were $24.71 million. The company’s total short-term debt was $2,659,000 while long-term debt stood at $0.
Sqz Biotechnologies Co’s total current assets stands at $27.69 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.56 million and inventory worth $0.
In 2024, Sqz Biotechnologies Co's operating cash flow was $0 while its capital expenditure stood at $47000.
Comparatively, Sqz Biotechnologies Co paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.05
- 52-Week High
- $3.388
- 52-Week Low
- $0.046
- Analyst Target Price
- $19
Sqz Biotechnologies Co stock is currently trading at $0.05 per share. It touched a 52-week high of $3.388 and a 52-week low of $3.388. Analysts tracking the stock have a 12-month average target price of $19.
Its 50-day moving average was $0.15 and 200-day moving average was $0.68 The short ratio stood at 27.26 indicating a short percent outstanding of 0%.
Around 312.3% of the company’s stock are held by insiders while 6658.1% are held by institutions.
Frequently Asked Questions About Sqz Biotechnologies Co
Similar Industry Stocks (Biotechnology & Medical Research)
Most Active
Top Gainers
Top Losers
About
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.